MENU

Will CSL’s share price go higher?

Australian-based biopharmaceutical company CSL (ASX: CSL) is undoubtedly a fantastic business that has created significant shareholder value. The impressive returns are partly thanks to the ‘moat’ CSL has.

While in theory the ‘moat’ is not particularly wide given the potential for competitors to discover ‘new and improved’ therapies that could displace those offered by CSL. In reality, the breadth of CSL’s product portfolio, coupled with its huge research and development spend and its economies of scale in the production of more ‘generic’ vaccine products all help to create a company with ‘moat’ attributes.

With talk in the financial news of stock markets around the world entering bubble territory and CSL’s own share price up 50% in the past 12 months to a new record high of  $69.75, some shareholders are surely asking themselves, will CSL’s share price go higher?

At least two leading stockbrokers seem to think so, with the Australian Financial Review reporting recently that both Bank of America Merrill Lynch and CSLA have ‘buy’ recommendations on the stock. However while there is positive market sentiment toward the stock, Foolish investors will know that at the end of the day it’s the valuation that counts.

According to CommSec, CSL is forecast to grow earnings per share (EPS) by just 0.7% and 11.7% over the next two financial years. This implies that CSL is trading on forecast price-to-earnings multiples of 26.3 and 23.6 respectively.

In comparison, fellow health sector companies such as Ramsay Health Care (ASX: RHC) and Sonic Healthcare (ASX: SHL) are forecast to have double-digit growth rates in EPS for the next two years and yet both trade on lower multiples than CSL – in Sonic’s case, substantially lower.

Foolish takeaway

Without a crystal ball, it’s impossible to know how far the stock market might rally or how high CSL’s share price may go. However based on consensus forecasts for growth in earnings, a conservative judgement of CSL’s valuation today would likely lead conservative investors to seeing limited upside from current prices.

Is your portfolio in need of a health check? Discover
The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research
report, including a full investment analysis! Simply click here for your FREE copy
of "The Motley Fool's Top Dividend Stock
for 2013-2014
."

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!